Dividends Inside 
Novartis AG Sponsored ADR
NVS
$143.28 (+ $2.49 + 1.77%)
Last updated: 2026-10-08 00:55 UTC
Novartis AG Sponsored ADR trades under ticker NVS on NYSE as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US66987V1098, CUSIP 66987V109. Also searched as Novartis AG Sponsored.
Related researchNVS stock priceNVS share priceNVS dividend historyNVS dividend yieldNovartis AG Sponsored dividend historyNovartis AG Sponsored dividend yield66987V109Novartis AG Sponsored stockNovartis AG Sponsored share price
About the Company
Novartis AG Sponsored ADR represents Novartis AG, a global healthcare company focused on developing, manufacturing, and commercializing prescription medicines and related healthcare products. Novartis serves major therapeutic areas including oncology, immunology, cardiovascular, neuroscience, and ophthalmology, with a portfolio built around innovative treatments for serious and chronic diseases. The company operates across research, development, production, and global distribution, supporting hospitals, physicians, and patients in markets worldwide. Novartis also includes medicines and platforms designed to improve access, formulation, and delivery of therapies, making it a significant participant in the pharmaceutical industry and the broader healthcare market. As a sponsored ADR, it provides U.S. investors with access to Novartis shares through an American depositary receipt structure.
Price History
Latest News for NVS
Tesla, SMCI, Others See Sharp Analyst Revisions
Sentiment shifts as risks and opportunities emerge
There Are Three Things Driving Amplify’s 5.1%. Yield Higher | IDVO
Most income ETFs draw from a single well: either dividends or options premium. The Amplify CWP International Enhanced Dividend Income ETF (NYSEARCA:IDVO) draws from three simultaneously, and the way it selects holdings is what separates it from passive income funds. The fund targets American Depositary Receipts, the dollar-denominated securities that let U.S. investors own shares ... There Are Three Things Driving Amplify’s 5.1%. Yield Higher | IDVO
Health Care Roundup: Market Talk
1127 ET – Novartis’s share-price strength this year raises the bar for upcoming data on late-stage clinical studies that will be pivotal for the Swiss drugmaker’s outlook, Bank of America analysts say in a research note. Pipeline failure could hit consensus estimates, but success would help shift investors’ focus away from patent expirations, according to Bank of America. Among Novartis’s upcoming phase 3 trials, Bank of America is most focused on remibrutinib in relapse-remitting multiple sclerosis and pelacarsen in secondary prevention of cardiovascular events, the analysts say.
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasisAdditional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s Ame
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut
Voyager Therapeutics (NASDAQ:VYGR) CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer blood-brain barrier (BBB)-penetrant capsid platform. Sandrock described 2026 as “the year of tau,” while also pointing to upcoming clinical
Stocks to Watch Recap: Super Micro Computer, FedEx, Unilever
↗️ FedEx (FDX): The shipping company raised its outlook as revenue increased in the fiscal third quarter. Shares rose 0.8%. ↘️ Super Micro Computer (SMCI): The technology company placed two employees on leave and fired a contractor after learning of their alleged involvement in a scheme to divert computer servers assembled in the U.